A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002

Indolent Systemic Mastocytosis Clinical Trial

Official title:
A Phase 1, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002 in Patients With Indolent Systemic Mastocytosis

Status Completed

Clinical Trial Summary

This is a Phase 1 study to investigate the safety and tolerability of AK002 in patients with indolent systemic mastocytosis (ISM).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02808793
Study type	Interventional
Source	Allakos, Inc.
Contact
Status	Completed
Phase	Phase 1
Start date	June 2016
Completion date	December 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04910685` - (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis	Phase 2/Phase 3
Completed	`NCT03632811` - Adaptation of the Questionnaire "Regarding Patient's Quality of Life With Mastocytosis" in the French Language
Completed	`NCT02478957` - Treatment of Indolent Systemic Mastocytosis With PA101	Phase 2
Completed	`NCT03770273` - Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis	Phase 2
Recruiting	`NCT04333108` - Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment	Phase 3
Not yet recruiting	`NCT06210698` - Angioedema Biomarker Research Study
Completed	`NCT00814073` - Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis	Phase 3
Active, not recruiting	`NCT01920204` - Midostaurin in Indolent Systemic Mastocytosis	Phase 2
Active, not recruiting	`NCT03731260` - (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis	Phase 2